Live
- Student Survives a Near-Fatal Accident at Pallavi Model School
- Prisoner in Sangareddy Central Jail Suffers Heart Attack
- Targeting gut cells may open new way to reduce depression & anxiety
- ‘Daaku Maharaaj’ to kickstart musical promotions
- ‘Game Changer’ team teases with a new promo
- Nara Lokesh emphasises overhaul of govt. schools and mid-day meal program
- Amid turmoil, air pollution peaks in Bangladesh as temperatures fall
- Google Trends unveils list of most searched ‘Indian Movies of 2024’
- BGT 2024-25: Hazlewood signals readiness for Brisbane Test after training with full run-up
- Google Presents Deep Research AI Tool for Comprehensive Web Reports
New liver cancer drug gets FDA approval
The U.S. Food & Drug Administration today approved a new drug to treat people with hepatocellular carcinoma, the most common form of liver cancer. The drug, regorafenib, is the first and only therapy approved by the FDA in over a decade to show significant improvement in survival for patients with the disease after standard treatments have failed.
The U.S. Food & Drug Administration today approved a new drug to treat people with hepatocellular carcinoma, the most common form of liver cancer. The drug, regorafenib, is the first and only therapy approved by the FDA in over a decade to show significant improvement in survival for patients with the disease after standard treatments have failed.
The research that led to the approval was conducted at UCLA and 21 other sites in the U.S., Europe and Asia. UCLA was the leader of the U.S. arm of the international collaboration, and the clinical studies were led by Dr. Richard Finn, an associate professor of medicine at the David Geffen School of Medicine and Director of the Signal Transduction and Therapeutics Program at UCLA’s Jonsson Comprehensive Cancer Center. "When liver cancer progresses to advanced stages, a cure is no longer possible," Finn said.
"Traditional treatments can help slow and control the disease for a short period of time, but eventually tumor growth will continue. Today’s approval of regorafenib is a major clinical advancement for patients when initial therapies are no longer working."
In the early and intermediate stages of the disease, doctors can treat patients only in the affected area of the liver with surgery, transplantation or traditional drug treatments such as chemotherapy. However, as the cancer progresses and localized treatments do not work, some people may be candidates for systemic therapies, Finn said.
